These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37778239)

  • 21. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
    Zhang S; Zhang Y; Chen X; Xu J; Fang H; Li Y; Liu Y; He H
    J Med Chem; 2022 Dec; 65(23):15856-15877. PubMed ID: 36384290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors.
    Jiang H; Fan Y; Wang X; Wang J; Yang H; Fan W; Tang C
    Bioorg Med Chem Lett; 2023 May; 88():129265. PubMed ID: 37011767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
    Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
    Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interaction.
    Ikram S; Sayyah E; Durdağı S
    Chembiochem; 2024 Jun; 25(12):e202400008. PubMed ID: 38622060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.
    Zhou C; Fan Z; Zhou Z; Li Y; Cui R; Liu C; Zhou G; Diao X; Jiang H; Zheng M; Zhang S; Xu T
    J Med Chem; 2022 Mar; 65(5):3923-3942. PubMed ID: 35230841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
    Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
    J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery.
    Wu J; Li X; Wu C; Wang Y; Zhang J
    Eur J Med Chem; 2024 Mar; 268():116282. PubMed ID: 38430853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
    Hamilton G; Stickler S; Rath B
    Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding SOS (Son of Sevenless).
    Pierre S; Bats AS; Coumoul X
    Biochem Pharmacol; 2011 Nov; 82(9):1049-56. PubMed ID: 21787760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of SOS1 Inhibitor-Based Degraders to Target
    Bian Y; Alem D; Beato F; Hogenson TL; Yang X; Jiang K; Cai J; Ma WW; Fernandez-Zapico M; Tan AC; Lawrence NJ; Fleming JB; Yuan Y; Xie H
    J Med Chem; 2022 Dec; 65(24):16432-16450. PubMed ID: 36459180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
    Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.
    Ni QZ; Zhu B; Ji Y; Zheng QW; Liang X; Ma N; Jiang H; Zhang FK; Shang YR; Wang YK; Xu S; Zhang EB; Yuan YM; Chen TW; Yin FF; Cao HJ; Huang JY; Xia J; Ding XF; Qiu XS; Ding K; Song C; Zhou WT; Wu M; Wang K; Lui R; Lin Q; Chen W; Li ZG; Cheng SQ; Wang XF; Xie D; Li JJ
    Adv Sci (Weinh); 2023 Jan; 10(2):e2202448. PubMed ID: 36453576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
    Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
    Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
    Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
    [No Abstract]   [Full Text] [Related]  

  • 36. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling.
    Abbott JR; Hodges TR; Daniels RN; Patel PA; Kennedy JP; Howes JE; Akan DT; Burns MC; Sai J; Sobolik T; Beesetty Y; Lee T; Rossanese OW; Phan J; Waterson AG; Fesik SW
    J Med Chem; 2018 Jul; 61(14):6002-6017. PubMed ID: 29856609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.
    Howes JE; Akan DT; Burns MC; Rossanese OW; Waterson AG; Fesik SW
    Mol Cancer Ther; 2018 May; 17(5):1051-1060. PubMed ID: 29440291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.
    Liu L; Song Z; Fan G; Lou L; Wang Y; Zhang X; Xiong XF
    Bioorg Med Chem; 2023 Oct; 93():117457. PubMed ID: 37688996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.